Teva Pharmaceutical Industries Limited Stock News

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.

Generic drug maker Teva Pharmaceuticals is to pay US $225 million in fines after admitting price-fixing on a range of drugs in the US. Teva and another firm it worked with, Glenmark Pharmaceuticals, h

Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholestoral to settle price-fixing charges from the US Department of Justice, the agency annou

CNBC's Bertha Coombs joins 'Closing Bell Overtime' with breaking news on the DOJ's antitrust agreement involving Teva and Glenmark.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. TEVA, +0.52%, said Monday that it has reached an agreement with the U.S. Department of Justice to settle criminal price-fi

It's the latest resolution in a string of cases related to price-fixing, referring to competitors banding together to artificially set the price of a product.

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.

Teva Pharmaceutical Industries Ltd has agreed to pay up to $126 million to U.S. hospitals over 18 years to settle claims that its marketing of opioid drugs raised the hospitals' operating costs.

Teva Pharmaceutical Industries , will still pursue launching a biosimilar for arthritis drug Humira next year despite a crowded marketplace, chief executive Richard Francis said on Wednesday.

Teva CEO Richard Francis joins 'Squawk on the Street' to discuss their Q2 earnings, what's next for the company, and more.

The headline numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metr

Teva Pharmaceutical Industries reported higher than expected second-quarter profit boosted by a jump in sales of its Austedo treatment for Huntington's Disease.

Teva Pharmaceuticals Industries Ltd. TEVA, +0.47% and Alvotech ALVO, +0.51% announced Monday that they are expanding their collaboration in the U.S. biosimilars market.

On August 2, 2023, Teva Pharmaceutical, one of the world's top generic drug manufacturers, will publish its financial report for the second quarter of 2023. The company has launched generic versions o

Analysts at UBS have upgraded their rating on Teva Pharmaceuticals, a manufacturer of generic pharmaceuticals, to ‘Neutral' from ‘Sell' citing a now balanced risk/reward profile. They also raised